West-Ward Columbus Inc Initiates Class III Recall of Methadone Hydrochloride Tablets Over Illegible Unit-Dose Labeling
West-Ward Columbus Inc has initiated a Class III recall of 2,591 boxes of Methadone Hydrochloride Tablets, 5mg, due to illegible unit-dose identification. This event, distributed by Hikma Pharmaceuticals USA Inc., signals potential dispensing errors and adds to West-Ward's history of quality control issues, demanding immediate attention from procurement and regulatory teams to assess supply chain risks and ensure patient safety.
Recall Details: FDA's Findings on Methadone Hydrochloride Tablets
West-Ward Columbus Inc, operating from its facility at 1809 Wilson Rd, Columbus, OH, United States (postal code 43228-9579), has initiated a voluntary Class III recall, identified as D-0183-2025, for its Methadone Hydrochloride Tablets, USP, 5mg. The recall, initiated on December 19, 2024, targets 2,591 100-count boxes of the product, specifically lot number AC2556A with an expiration date of March 2027. The primary reason for this action is a failure in tablet/capsule specifications: illegible product identification on the unit dose configuration. These tablets, distributed by Hikma Pharmaceuticals USA Inc., Berkeley Heights, NJ 07922, are designated for US Nationwide distribution. For procurement directors, this means an immediate assessment of inventory holding and potential disruption for Methadone Hydrochloride, a critical human prescription drug (ANDA088109, NDC 0054-0709-20, 0054-0710-25). The illegibility of product identification, even on unit-dose packaging, poses a direct risk of dispensing errors, impacting patient safety and increasing liability for downstream pharmacies and healthcare providers. Regulatory affairs heads must ensure their internal systems are robust enough to track such Class III recalls and communicate potential impacts to their stakeholders, particularly concerning products distributed under their brand.
Operational Impact and Supply Chain Vulnerabilities for Methadone Hydrochloride
The recall of Methadone Hydrochloride Tablets, USP, 5mg, by West-Ward Columbus Inc highlights a critical vulnerability in the pharmaceutical supply chain related to packaging integrity. While a Class III recall typically indicates a situation where the probability of serious adverse health consequences is remote, the specific defect—illegible product identification on unit-dose configurations—carries significant operational implications. For supply chain VPs, this necessitates a review of quality control checkpoints, not just at the manufacturing stage but also during packaging and labeling. The product, identified by NDCs such as 0054-0709 and 0054-0710, is widely distributed across the US, suggesting a broad impact on pharmacies and treatment centers relying on consistent, clearly identifiable medication. Business development executives should note that such incidents can erode trust in supplier reliability, prompting customers to seek alternative sources. The ongoing status of this recall, reported on January 15, 2025, means that the affected lot remains a concern in the market, requiring continuous monitoring of its removal and destruction. This event underscores the need for robust quality agreements with manufacturers, explicitly detailing requirements for packaging legibility and verification processes, to mitigate risks associated with essential medicines like Methadone Hydrochloride.
West-Ward Columbus Inc's Recurring Quality Control Challenges
This latest Class III recall for Methadone Hydrochloride Tablets is not an isolated incident for West-Ward Columbus Inc, suggesting a pattern of recurring quality control challenges within the company's manufacturing operations. ChemLifeIntel's intelligence indicates two prior significant recalls initiated by West-Ward Columbus Inc in 2020. In May 2020, the company faced a recall for Ethacrynic Acid, which signaled persistent impurity control challenges impacting the US supply chain. Shortly thereafter, in June 2020, West-Ward Columbus Inc initiated a Class II recall for Doxycycline Hyclate Tablets due to dissolution failure. For procurement directors, this history of quality issues across different product categories—from impurity control to dissolution and now labeling integrity—should trigger a heightened level of scrutiny. It implies that the company's quality management systems may have systemic weaknesses rather than isolated product-specific problems. Regulatory affairs heads must recognize that a documented history of recalls, even if individually classified as Class III, can lead to increased FDA oversight and more stringent inspection criteria in the future. This trend necessitates a thorough re-evaluation of West-Ward Columbus Inc as a supplier, demanding comprehensive due diligence beyond standard audits.
Strategic Considerations for Procurement and Risk Mitigation
In light of West-Ward Columbus Inc's repeated quality control issues, including the current Methadone Hydrochloride recall, procurement directors and supply chain VPs must implement enhanced risk mitigation strategies. A primary consideration is the diversification of sourcing for critical molecules like Methadone Hydrochloride to avoid over-reliance on a single manufacturer with a documented history of compliance challenges. While specific alternative suppliers for Methadone Hydrochloride are not detailed in this intelligence, proactive identification and qualification of secondary and tertiary sources are paramount. Furthermore, supplier qualification processes must evolve beyond initial assessments to include continuous monitoring of regulatory actions and quality performance metrics. This involves not only reviewing FDA recall notices but also tracking the nature and frequency of such events. Business development executives should leverage this intelligence to identify market opportunities where competitors may be vulnerable due to supplier quality issues. The 'Voluntary: Firm initiated' nature of this recall, while indicating some level of internal vigilance, does not negate the underlying quality system deficiencies that allowed the illegible labeling to reach the market. Robust internal audits and a clear understanding of supplier CAPA (Corrective and Preventive Actions) plans are essential to safeguard supply chain integrity and patient safety.
Regulatory Outlook and Future Scrutiny for West-Ward Columbus Inc
The FDA's classification of the Methadone Hydrochloride recall as Class III, while indicating a lower immediate health risk, does not diminish the long-term regulatory implications for West-Ward Columbus Inc. The 'Ongoing' status of the recall signifies that the FDA continues to monitor the firm's actions to effectively remove the affected product from distribution and address the root cause of the illegible labeling. For regulatory affairs heads, this event, coupled with the company's prior recalls for Ethacrynic Acid and Doxycycline Hyclate, suggests an escalating pattern of non-compliance that could invite more intense scrutiny from the agency. Repeated quality failures, even if individually minor, can aggregate into a perception of systemic control deficiencies, potentially leading to more severe regulatory actions such as Warning Letters, consent decrees, or even import alerts on specific products or facilities. West-Ward Columbus Inc will be expected to provide a comprehensive corrective and preventive action (CAPA) plan to the FDA, detailing how it will prevent similar labeling defects in the future. This situation underscores the critical need for pharmaceutical manufacturers to invest in robust quality systems that ensure consistent product identification and overall manufacturing compliance, thereby protecting both their market access and their reputation.